{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:28:01Z","timestamp":1772670481306,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or \u03b2-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, \u03b2-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or \u03b2-blockers. The adverse reaction rates seem similar between SLIT products.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>A risk-versus-benefit discussion should be communicated with the patient taking a \u03b2-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aci.0000000000000657","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T09:47:07Z","timestamp":1592905627000},"page":"401-406","source":"Crossref","is-referenced-by-count":5,"title":["\u03b2-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile?"],"prefix":"10.1097","volume":"20","author":[{"given":"Derek M.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Coop","sequence":"additional","affiliation":[{"name":"Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore M.","family":"Freeman","sequence":"additional","affiliation":[{"name":"San Antonio Asthma and Allergy Clinic, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R5-20230827","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"key":"R6-20230827","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.12638","article-title":"Clinical contraindications to allergen immunotherapy: an EAACI position paper","volume":"70","author":"Pitsios","year":"2015","journal-title":"Allergy"},{"key":"R7-20230827","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaip.2018.10.042","article-title":"Relationship between anaphylaxis and use of beta-blockers and angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis of observational studies","volume":"7","author":"Tejedor-Alonso","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R8-20230827","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaci.2014.09.004","article-title":"Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming","volume":"135","author":"Nassiri","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R9-20230827","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199106203242506","article-title":"Anaphylaxis","volume":"324","author":"Bochner","year":"1991","journal-title":"N Engl J Med"},{"key":"R10-20230827","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/ACI.0000000000000468","article-title":"Pitfalls in anaphylaxis","volume":"18","author":"De Feo","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R11-20230827","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.anai.2016.02.014","article-title":"Safety and tolerability during build-up phase of a rush venom immunotherapy","volume":"116","author":"Bernkopf","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R12-20230827","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0140-6736(92)93314-D","article-title":"ACE inhibitors and anaphylactoid reactions during venom immunotherapy","volume":"340","author":"Tunon-de-Lara","year":"1992","journal-title":"Lancet"},{"key":"R13-20230827","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0091-6749(03)01940-7","article-title":"Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor","volume":"112","author":"Ober","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"R14-20230827","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1081-1206(10)60321-3","article-title":"Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy","volume":"101","author":"White","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R15-20230827","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2500\/aap.2008.29.3141","article-title":"Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors","volume":"29","author":"Rank","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"R16-20230827","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/cea.12276","article-title":"Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase","volume":"44","author":"Stoevesandt","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"R17-20230827","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.anai.2015.03.001","article-title":"Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective","volume":"114","author":"Stoevesandt","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R18-20230827","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaci.2005.12.002","article-title":"Anaphylaxis, killer allergy: long-term management in the community","volume":"117","author":"Simon","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20230827","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.anai.2016.12.009","article-title":"Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update","volume":"118","author":"Greenhawt","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R20-20230827","first-page":"929","article-title":"Beta-blocker therapy and the risk of anaphylaxis","volume":"136","author":"Toogood","year":"1987","journal-title":"Can Med Assoc J"},{"key":"R21-20230827","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaip.2017.12.020","article-title":"Patients taking \u03b2-blockers do not require increased doses of epinephrine for anaphylaxis","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R22-20230827","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/emj.2005.023507","article-title":"Best evidence topic report: glucagon infusion in refractory anaphylactic shock in patients on beta-blockers","volume":"22","author":"Thomas","year":"2005","journal-title":"Emerg Med J"},{"key":"R23-20230827","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11882-008-0008-8","article-title":"Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?","volume":"8","author":"Lang","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"key":"R24-20230827","first-page":"35","article-title":"Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride","volume":"47","author":"Newman","year":"1981","journal-title":"Ann Allergy"},{"key":"R25-20230827","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0091-6749(87)80164-1","article-title":"Fatalities from immunotherapy (IT) and skin testing (ST)","volume":"79","author":"Lockey","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"R26-20230827","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaci.2005.10.010","article-title":"Evaluation of near-fatal reactions to allergen immunotherapy injections","volume":"117","author":"Amin","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R27-20230827","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaci.2010.04.025","article-title":"Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase","volume":"126","author":"Ru\u00ebff","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R28-20230827","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaci.2004.11.012","article-title":"Use of beta-blockers during immunotherapy for Hymenoptera venom allergy","volume":"115","author":"M\u00fcller","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R29-20230827","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis: a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R30-20230827","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2016.10.031","article-title":"Stinging insect hypersensitivity: a practice parameter update 2016","volume":"118","author":"Golden","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R31-20230827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-017-0225-6","article-title":"CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens","volume":"14","author":"Quirt","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R32-20230827","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R33-20230827","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaci.2016.09.043","article-title":"Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite\u2013induced allergic rhinitis","volume":"139","author":"Okubo","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R34-20230827","doi-asserted-by":"crossref","first-page":"84.e9","DOI":"10.1016\/j.jaip.2016.08.017","article-title":"Epinephrine use in clinical trials of sublingual immunotherapy tablets","volume":"5","author":"Nolte","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R35-20230827","doi-asserted-by":"crossref","first-page":"435.e43","DOI":"10.1111\/all.12996","article-title":"House dustmite sublingual tablet is effective and safe in patients with allergic rhinitis","volume":"72","author":"Okamoto","year":"2017","journal-title":"Allergy"},{"key":"R36-20230827","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/pai.12984","article-title":"Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: a randomized trial in a pediatric population","volume":"30","author":"Okamoto","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"R37-20230827","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaip.2018.11.044","article-title":"Long-term efficacy and dose-finding trial of Japanese cedar pollen sublingual immunotherapy tablet","volume":"7","author":"Gotoh","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R38-20230827","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/all.13606","article-title":"A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group","volume":"74","author":"Couroux","year":"2019","journal-title":"Allergy"},{"key":"R39-20230827","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jaci.2018.12.1001","article-title":"The SQ tree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"143","author":"Biedermann","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T03:30:15Z","timestamp":1693107015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000657","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}